A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5587-5591

  Gu, Ming ^a   Li, Su Yi ^a   Huang, Xin En ^b   Lin, Yah ^c   Cheng, Hong Yan ^a   Liu, Liu ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

5 Fu; Chemotherapy; Continuous intravenous infusion; Esophageal squamous cell cancer; Paclitaxel

Indexed keywords

EID: 84874047793     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5587     Document Type: Article

References (41)

1. Al-Batran SE, Ajani JA (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116, 2511-8.
2. Bhatt RS, Merchan J, Parker R, et al (2010). A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 116, 1751-1756.
3. Breathnach OS, Georgiadis MS, Schuler BS, et al (2000). Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced nonsmall cell lung cancer. Clin Cancer Res, 6, 2670-6.
4. Bucci MK, Rosenthal DI, Hershock D, et al (2004). Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol, 27, 595-602.
5. Ekman S, Dreilich M, Lennartsson J, et al (2008). Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther, 8, 1433-48.
6. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
7. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.
8. Hainsworth JD, Meluch AA, Greco FA, et al (1997). Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Semin Oncol, 24, S19-38-S19-42.
9. Herskovic A, Russell W, Liptay M, et al (2012). Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol, 23, 1095-103.
10. Holmes FA, Valero V, Buzdar AU (1998). Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer: the long and the short of it. Proc Am Soc Clin Oncol, 17, 110a (Abstr 426).
11. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
12. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
13. Kato K, Tahara M, Hironaka S, et al (2011). A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol, 67, 1265-72.
14. Langer CJ, Harris J, Horwitz EM, et al (2007). Phase II study of low-dose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25, 4800-5.
15. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.
16. Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
17. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
18. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
19. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum.Asian Pac J Cancer Prev, 13, 2409-14.
20. Markman M, Rose PG, Jones E et al (1998). Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer previously failing treatment with 3-hour or 24-hour paclitaxel regimens. J Clin Oncol, 16, 1849-51.
21. Mirinezhad SK, Somi MH, Jangjoo AG, et al (2012). Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-4.
22. Orditura M, Galizia G, Napolitano V, et al(2010) Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest, 28, 820-7.
23. Pasial P, Philippe R (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol, 16, 301-8.
24. Polee MB, Eskens FA, van der Burg ME, et al(2002). Phase II study of biweeklyadministration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.Br J Cancer, 86, 669-73.
25. Seidman AD, Hochhauser D, Gollub M, et al (1996). Ninetysix hour paclitaxel infusion after progression during taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol, 14, 1877-84.
26. Shade RJ, Pisters KM, Huber MH, et al (1998-1999). Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs, 16, 237-43.
27. Socinski MA, Mudd PN, Radomski KM, et al (1998). Phase I trial of a 96-h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anticancer Drugs, 9, 611-9.
28. Socinski MA, Steagall A, Gillenwater H(1999). Second-line chemotherapy with 96-hour infusional paclitaxel I refractory non-small cell lung cancer: report of a Phase II trial. Cancer Invest, 17, 181-8.
29. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.
30. Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Nat Med J China, 90, 1986-8.
31. West HL, Crowley JJ, Vance RB, et al(2005). Advanced bronchioloalveolar carcinoma: a phase ? trial of paclitaxel by 96-hour infusion (SWOG 9714) : a Southwest Oncology Group study. Ann Oncol, 16, 1076-80.
32. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
33. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
34. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12,3087-90.
35. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.
36. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
37. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
38. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.
39. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
40. Zhang XZ, Huang XE, Xu YL, et al (2012). A phase II study on voriconazole in treating chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.
41. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.